Testosterone replacement therapy in males with erectile dysfunction

Journal of Pharmacy Practice

Volumn 24, Issue 3, 2011, Pages 298-306

  Jacob, Bobby C ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

erectile dysfunction; hypogonadism; sexual dysfunction; testosterone; testosterone deficiency

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; PLACEBO; SILDENAFIL; TADALAFIL; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ANDROGEN DEFICIENCY; ARTICLE; BREAST CANCER; COUGHING; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; EJACULATION; ERECTILE DYSFUNCTION; ERYTHROCYTOSIS; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INFECTION; INJECTION SITE PAIN; LIBIDO; MICTURITION; MONOTHERAPY; MOOD CHANGE; NONHUMAN; PENIS ERECTION; PROSTATE CANCER; PROSTATECTOMY; SIDE EFFECT; SKIN IRRITATION; SLEEP APNEA SYNDROME; TASTE; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE;

EID: 79958083970     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010397715     Document Type: Article

References (76)

1. NIH Consens Statement. 1992 ; 10 (4). 7 1-9 31
2. Ginsberg TB. Male sexuality. Clin Geriatr Med. 2010 ; 26 (2). 185-195
3. Folsom C, Fesperman SF, Tojuola B, et al. Direct to consumer advertising for urological pharmaceuticals: a cross sectional analysis of print media. Urol. 2010 ; 75 (5). 1029-1033
4. Waack KE, Ernst ME, Graber MA. Informational content of official pharmaceutical industry websites about treatments for erectile dysfunction. Ann Pharmacother. 2004 ; 38 (12). 2029-2034 (Pubitemid 40169370)
5. Curtiss FR. United states, the last venue for direct to consumer advertising, props up the erectile dysfunction market. JMCP. 2005 ; 11 (2). 176-177
6. Rosen RC, Cappelleri JC, Gendrano N. The international index of erectile function (IIEF): a state of the science review. Int J Impot Res. 2002 ; 14 (4). 226-244 (Pubitemid 34947726)
7. Mulhall JP, McLaughlin TP, Harnett JP, et al. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med. 2005 ; 2 (6). 848-855 (Pubitemid 41727398)
8. National Center for Health Statistics. Older persons' health. http://www.cdc.gov/nchs/fastats/older-americans.htm. Accessed September 1, 2010.
9. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some policy consequences. BJU Int. 1999 ; 84 (1). 50-56 (Pubitemid 29346774)
10. Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003 ; 139 (3). 161-168
11. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 ; 151 (1). 54-61 (Pubitemid 24046934)
12. McVary KT. Erectile dysfunction. NEJM. 2007 ; 357: 2472-2481 (Pubitemid 350272786)
13. Bhasin S, Basson R Williams Textbook of Endocrinology. ronenberg HM Melmed S Polonsky KS Larsen PR, ed. Philadelphia, PA: Saunders Elsevier ; 2008: 701-737.
14. Wylie K, Kenney G. Sexual dysfunction and the aging male. Maturitas. 2010 ; 65 (1). 23-27
15. Bain J. The many faces of testosterone. Clin Intervent Aging. 2007 ; 2 (4). 567-576
16. McVary KT Harrison's principles of internal medicine. Fauci AS Braunwald E Kasper DL, ed. New York, NY: McGraw-Hill ; 2008 :
17. Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010 ; 7: 445-475
18. Yassin AA, Saad F. Testosterone and erectile dysfunction. J Androl. 2008 ; 29: 593-604
19. Lue TF. Erectile dysfunction. NEJM. 2000 ; 342 (24). 1802-1813 (Pubitemid 30390241)
20. Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010 ; 7 (4 pt 2). 1627-1656
21. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006 ; 3: 382-407
22. Shabsigh R, Rajfer J, Aversa A, et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract. 2006 ; 60 (9). 1087-1092 (Pubitemid 44226747)
23. Hwang TI, Lin YC. The relationship between hypogonadism and erectile dysfunction. Int J Impot Res. 2008 ; 20 (3). 231-235 (Pubitemid 351684727)
24. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol. 2007 ; 52 (1). 54-70 (Pubitemid 46803026)
25. Buvat J, Jaoude GB. Significance of hypogonadism in erectile dysfunction. World J Urol. 2006 ; 24 (6). 657-667 (Pubitemid 44896707)
26. Gurbuz N, Mammadov E, Usta MF. Hypogonadism and erectile dysfunction: an overview. Asian J Androl. 2008 ; 10 (1). 36-43
27. Blute M, Hakimian P, Kashanian J, et al. Erectile dysfunction and testosterone deficiency. Front Horm Res. 2009 ; 37: 108-122
28. Kohler TS, Kim J, Feia K, et al. Prevalence of androgen deficiency in men with erectile dysfunction. Urol. 2008 ; 71 (4). 693-697
29. Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EAU, EAA, and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res. 2009 ; 21: 1-8
30. Tajar A, Forti G, O'neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male aging study. J Clin Endocrinol Metab. 2010 ; 95 (4). 1810-1818
31. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 ; 60 (7). 762-769 (Pubitemid 43881152)
32. Schneider HJ, Sievers C, Klotsche J, et al. Prevalence of low male testosterone levels in primary care in Germany: cross-sectional results from the DETECT study. Clin Endocrinol. 2009 ; 70 (3). 446-454
33. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004 ; 89 (12). 5920-5926 (Pubitemid 39628393)
34. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007 ; 92 (11). 4241-4247 (Pubitemid 350074738)
35. Liu C, Wu W, Lee Y, et al. The prevalence of and risk factors for androgen deficiency in aging Taiwanese men. J Sex Med. 2009 ; 6 (4). 936-946
36. Petak SM, Nankin HR, Spark RF, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hygogonadism in adult male patients. Endo Pract. 2002 ; 8 (6). 439-456
37. Bhasin S, Jameson L Harrison s principles of internal medicine. Fauci AS Braunwald E Kasper DL, ed. New York, NY: McGraw-Hill ; 2008 :
38. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010 ; 96 (6). 2536-2559
39. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006 ; 91 (11). 4335-4343 (Pubitemid 44833407)
40. Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol. 2010 ; 121 (3-5). 513-519
41. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000 ; 85 (8). 2839-2853 (Pubitemid 32269162)
42. Wang C, Cunningham G, Dobs A, et al. Long term testosterone gel (androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004 ; 89 (5). 2085-2098 (Pubitemid 38619836)
43. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003 ; 88 (6). 2673-2681 (Pubitemid 36724441)
44. Allan CA, Forbes EA, Strauss BJG, et al. Testosterone therapy increases sexual desire in aging men with low normal testosterone levels and symptoms of androgen deficiency. Int J Impot Res. 2008 ; 20: 396-401
45. Mulhall JP, Valenzuela R, Aviv N, et al. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urol. 2004 ; 63 (2). 348-353
46. Corona G, Petrone L, Fisher AD, et al. Six month administration of 1% testosterone gel is able to restore erectile function in hypogonadal patients with erectile dysfunction. Andrologia. 2008 ; 80 (3). 103-108
47. Karazindiyanoglu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late onset hypogonadism. The Aging Male. 2008 ; 11 (3). 146-149
48. Greenstein A, Mabjeesh NJ, Sofer M, et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?. J Urol. 2005 ; 173 (2). 530-532
49. Chiang HS, Hwang TIS, Hsui YS, et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res. 2007 ; 19 (4). 411-417 (Pubitemid 47026092)
50. Saad F, Gooren L, Haider A, et al. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia. 2008 ; 40 (1). 44-48
51. Moon DG, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido) in testosterone deficiency syndrome in Korean: a multi-center prospective study. J Sex Med. 2010 ; 7: 2253-2260
52. Jockenhovel F, Minnemann T, Schubert M, et al. Comparison of long acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol. 2009 ; 160 (5). 815-819
53. Greco EA, Spera G, Aversa A. Combining testosterone and PDE-5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol. 2006 ; 50: 940-947 (Pubitemid 44486492)
54. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open label uncontrolled study. Andrologia. 2006 ; 38 (2). 61-68
55. Rosenthal BD, May NR, Metro MJ, et al. Adjunctive use of androgel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urol. 2006 ; 67 (3). 571-574 (Pubitemid 43343545)
56. Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE-5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2010 ;:
57. Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004 ; 172 (2). 658-663 (Pubitemid 38900229)
58. Presti JC, Kane CJ, Shinohara K, et al Smith's General Urology. Tanagho EA McAninch JW, ed. New York, NY: McGraw-Hill ; 2008 :
59. Khera M. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009 ; 6 (suppl 3). 234-238
60. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005 ; 173 (2). 533-536
61. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004 ; 172 (3). 920-922 (Pubitemid 39096423)
62. Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 ; 6 (4). 1165-1170
63. Clinical Trials. Testosterone for penile rehab after radical prostatectomy. http://clinicaltrials.gov/ct2/show/NCT00848497. Updated: March 4, 2010. Access September 1, 2010.
64. Rhoden EL, Averbeck MA, Teloken PE. Androgen replacement in men undergoing treatment for prostate cancer. J Sex Med. 2008 ; 5 (9). 2202-2208
65. Shabsigh R, Crawford ED, Nehra A, et al. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systemic review. Int J Impot Res. 2009 ; 21: 9-23
66. Institute of Medicine. Testosterone and Aging: Clinical Research Directions. http://www.nap.edu/openbook.php?record-id=10852&page=1. Accessed September 1, 2010.
67. Marietta, GA: Solvay Pharmaceuticals, Inc. ; 2009 :
68. Malvern, PA: Auxillium Pharmaceuticals, Inc. ; 2009 :
69. Kalamazoo, MI: Pharmacia Corporation ; 2002 :
70. Livingston, NJ: Columbia Laboratories, Inc. ; 2003 :
71. Slate Pharmaceuticals, Inc ; 2009 :
72. American Urological Association. Management of Erectile Dysfunction. 2005. http://www.auanet.org/content/guidelines-and-quality-care/clinical- guidelines.cfm?sub=ed&CFID=3180273&CFTOKEN=34484910&jsessionid= 8430cb85c1c602c363b02d7d4b2d61362915. Accessed September 1, 2010.
73. United States Food and Drug Administration. Testosterone Gel Safety Concerns Prompt FDA to Require Label Changes, Medication Guide. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149580.htm. Updated: May 7, 2009. Accessed September 1, 2010.
74. Kunz GJ, Klein KO, Clemons RD, et al. Virilization of young children after topical androgen use by their parents. Pediatrics. 2004 ; 114 (1). 282-284 (Pubitemid 38857604)
75. Franklin SL, Geffner ME. Precocious puberty secondary to topical testosterone exposure. J Pediatr Endocrinol Metab. 2003 ; 16 (1). 107-110 (Pubitemid 37259100)
76. Yu YM, Punyasavatsu N, Elder D, D'Ercole AJ. Sexual development in a two year old body induced by topical exposure to testosterone. Pediatrics. 1999 ; 104 (2). e23